Donaldson Company Invests in New Life Sciences Technical Center
09 November 2023 - 4:45PM
Business Wire
Research Triangle Park, a North Carolina
technology and biotech hub, is Donaldson’s choice for the latest
expansion of its life sciences footprint
Donaldson Company, Inc. (NYSE: DCI), a leading worldwide
provider of innovative filtration products and solutions, announced
its commitment to broadening its life sciences reach with the
opening of a 25,000-square-foot life sciences technical center in
Research Triangle Park (RTP). Donaldson brands located or under
development at the facility include Isolere Bio, Purilogics,
Solaris Biotech and Univercells Technologies.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20231109952859/en/
Donaldson Isolere Bio team developing
novel, proprietary IsoTag reagents. (Photo: Business Wire)
The technical center at 5 Lab Drive in RTP is centrally located
on a campus supporting emerging biotechnology companies and
includes modern laboratories as well as cleanrooms that provide
product manufacturing capacity. The new facility will support the
design, development, launch and early commercialization of
transformational bioprocessing solutions. It also will serve as a
hub for Donaldson life science innovations while advancing the
IsoTag™ reagent product line.
“RTP is the perfect strategic location to attract world-class
talent to our growing team, deploy enabling bioprocessing
solutions, and engage with leading cell and gene therapy players,”
said Andrew Dahlgren, Donaldson Life Sciences president. The
facility provides Donaldson with the resources necessary to
increase development, collaboration and operations.
Donaldson recently launched Isolere Bio’s first product, IsoTag™
AAV, for the purification of adeno-associated viral vectors (AAV).
The novel reagent uses affinity liquid-phase separation paired with
efficient microfiltration for the purification and streamlined
manufacturing of AAV, vectors critical to the gene therapy
industry. Prototype-grade material from the second product line,
IsoTag™ LV for lentiviral vectors, is scheduled to launch in early
2024.
“Through this meaningful investment, we are now poised to
accelerate commercialization of our IsoTag technology and deliver
disruptive solutions to our customers in the advanced therapeutics
space,” said Kelli Luginbuhl, Donaldson Isolere Bio business
director. “By adding manufacturing capacity, Donaldson is in a
stronger position to support customers in their research through
clinical and commercial-scale activities.”
About Donaldson Company,
Inc.
Founded in 1915, Donaldson (NYSE: DCI) is a global leader in
technology-led filtration products and solutions, serving a broad
range of industries and advanced markets. Diverse, skilled
employees at more than 140 locations on six continents partner with
customers — from small business owners to R&D organizations and
the world’s biggest OEM brands. Donaldson solves complex filtration
challenges through three primary segments: Mobile Solutions,
Industrial Solutions and Life Sciences. Additional information is
available at www.Donaldson.com and www.isolerebio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231109952859/en/
Sarika Dhadwal (952) 887-3753 Sarika.Dhadwal@Donaldson.com
Donaldson (NYSE:DCI)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Donaldson (NYSE:DCI)
Historical Stock Chart
Von Mai 2023 bis Mai 2024